• RapidSX is a patent-pending, column-based solvent extraction technology that offers a transformative leap over traditional methods.
• The Strategic Metals Complex in Alexandria, Louisiana, serves as the proving ground for RapidSX technology.
• Ucore’s RapidSX technology has undergone rigorous testing and independent evaluations, consistently demonstrating superior performance.

In the race to secure a sustainable and independent supply of rare earth elements (“REEs”), Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF) stands at the forefront with its groundbreaking RapidSX(TM) technology. This innovative approach to REE separation promises to significantly enhance processing efficiency, reduce environmental impact and bolster the United States’ position in the global rare earth supply chain (https://ibn.fm/i5Uol). At the heart of this initiative is the Strategic Metals Complex (“SMC”) in Alexandria, Louisiana, a facility poised to become a cornerstone in the nation’s critical minerals infrastructure.

RapidSX is a patent-pending, column-based solvent extraction technology that offers a transformative leap over traditional methods (https://ibn.fm/wN0hg). Unlike conventional solvent extraction processes that rely on power-intensive mixer-settler tanks, RapidSX utilizes a computerized column system, resulting in up to three times faster processing speeds and a significantly smaller physical footprint. This efficiency translates to reduced capital and operational expenditures, making it a cost-effective solution for large-scale REE production. Additionally, the technology’s modular design allows for scalability, enabling incremental capacity additions to meet growing demand.

The environmental advantages of RapidSX are equally compelling. By eliminating the need for traditional mixer-settler tanks, the technology reduces the consumption of process chemicals and minimizes waste generation. This ecofriendly approach aligns with global sustainability goals and positions Ucore as a leader in responsible rare earth processing.

The Strategic Metals Complex in Alexandria, Louisiana, serves as the proving ground for RapidSX technology (https://ibn.fm/QdeyR). Spanning 80,800 square feet, the facility is being developed under a long-term lease agreement with the England Authority, which manages the England Airpark, a repurposed U.S. Air Force base transformed into a regional economic hub. With the support of an $18.4 million grant from the U.S. Department of Defense, Ucore aims to commence production in 2026, targeting an annual output of 2,000 tonnes of high-purity rare earth oxides, with plans to scale up to 7,500 tonnes by 2028.

This facility is not only a testament to Ucore’s technological advancements but also a strategic move to diversify the U.S. supply chain for critical minerals. The Louisiana SMC is designed to process mixed rare earth chemical concentrates obtained from multiple global feedstock sources, including the Tanbreez Project in Greenland. Ucore recently signed a 10-year agreement with Critical Metals Corp. to supply up to 10,000 metric tons of heavy rare earth concentrate annually from Tanbreez, aligning with the U.S. government’s strategy to reduce reliance on China, which currently dominates the rare earth sector (https://ibn.fm/x8HPs).

Ucore’s RapidSX technology has undergone rigorous testing and independent evaluations, consistently demonstrating superior performance compared to traditional solvent extraction methods (https://ibn.fm/PA2fm). For instance, studies have shown that RapidSX can achieve separation factors within less than 100 seconds, outperforming conventional processes in both speed and efficiency.

Looking ahead, Ucore plans to expand its footprint with additional Strategic Metals Complexes in Canada and Alaska, further solidifying its position in the global rare earth supply chain (https://ibn.fm/wcMVP). With the continued development of RapidSX technology and the strategic establishment of processing facilities like the one in Louisiana, Ucore Rare Metals is poised to play a pivotal role in reshaping the future of rare earth element production and processing.

For more information, visit www.Ucore.com.

NOTE TO INVESTORS: The latest news and updates relating to UURAF are available in the company’s newsroom at https://ibn.fm/UURAF

• The FDA’s orphan drug designation for dusquetide follows encouraging phase 2a clinical trial results demonstrating both biological efficacy and a favorable safety profile.
• CEO notes that “the FDA’s decision to grant orphan drug designation to the SGX945 program signifies an important step for Soligenix.”
• Phase 2a pilot data demonstrated clinically meaningful improvements in oral aphthous ulcer healing.

Soligenix (NASDAQ: SNGX) has taken a decisive step forward in the fight against rare diseases, announcing that the FDA has granted orphan drug designation to its investigational therapy dusquetide for the treatment of Behçet’s disease (https://ibn.fm/0t1aK). This key FDA designation underscores not only the strength of recent phase 2 results but also the company’s growing reputation as a late-stage biopharmaceutical innovator dedicated to tackling serious, underserved conditions. 

The FDA’s orphan drug designation for dusquetide follows encouraging phase 2a clinical trial results demonstrating both biological efficacy in reducing oral aphthous ulcers and a favorable safety profile in patients with Behçet’s disease (https://ibn.fm/idr7M). The designation not only highlights the promise of Soligenix’s SGX945 program but also unlocks critical development incentives, such as seven years of U.S. market exclusivity upon approval, potential government grant support, fee waivers and valuable tax credits. 

“Behçet’s disease is an area of unmet medical need, with up to 18,000 people in the U.S., 50,000 in Europe, 350,000 people in Turkey and as many as one million people worldwide affected by this incurable disease,” said Soligenix CEO Dr. Christopher J. Schaber. “Given the clinically meaningful improvements seen in a phase 2 proof-of-concept study in patients with oral aphthous ulcers due to Behçet’s disease, we are hopeful dusquetide will have a role to play in helping underserved patients suffering from this difficult to treat and chronic autoimmune disease. The FDA’s decision to grant orphan drug designation to the SGX945 program signifies an important step for Soligenix as we continue to advance the program and adds significantly to the existing intellectual property estate surrounding this novel technology.”

Characterized by painful redness, swelling and ulceration of the mucous membranes in the mouth, oral mucositis is a common and debilitating condition often triggered by chemotherapy, radiotherapy or hematopoietic stem cell transplantation. The condition causes severe pain, disrupts oral intake and can lead to infections or require nutritional interventions such as parenteral feeding. In extreme cases, treatment protocols may be interrupted or dosage reduced, negatively impacting patient outcomes. Because it compromises patients’ ability to speak, eat and swallow, oral mucositis significantly diminishes quality of life and poses serious challenges in the management of cancer and other treatments.

Soligenix’s development work with dusquetide, specifically targeting oral ulcers, taps into the broader medical need to address oral mucositis effectively. The company’s SGX945 (dusquetide) has earned both fast-track and orphan drug designations for its role in treating oral lesions in Behçet’s disease, further emphasizing the potential overlap with mucositis management  Dusquetide belongs to a class of innate defense regulators (“IDRs”) that modulate the immune response to promote healing, reduce inflammation and protect tissues, an approach that may have meaningful implications for alleviating painful mouth ulcers in Behçet’s patients and possibly beyond.

Phase 2a pilot data demonstrated clinically meaningful improvements in oral aphthous ulcer healing, with SGX945 proving well-tolerated and showing no significant adverse effects, a notable contrast to current treatments such as apremilast, known for common side effects such as headache, nausea and diarrhea. This emerging evidence underscores Soligenix’s potential to address a critical unmet need and improve patient outcomes in an underserved population.

By combining regulatory incentives, clinical traction and a compelling therapeutic strategy, Soligenix is establishing a solid development pathway for SGX945. The orphan designation strengthens the company’s IP position and paves the way for future clinical development. As Soligenix advances its SGX945 program, it reinforces its overarching mission to develop novel treatments for rare and challenging conditions, including its ongoing progress with its ricin toxin vaccine candidate (https://ibn.fm/g2Hkx), moving the company closer to delivering impactful therapies to patients in need.

For more information, visit www.Soligenix.com.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

• VMAR’s record underscores company’s commitment to innovation and excellence in the electric marine industry.
• CEO notes that company is “in a bold new development and training phase.”
• Company’s E-Motion 180E is a high-performance, 180-horsepower electric outboard motor designed to deliver exceptional speed and efficiency.

Vision Marine Technologies (NASDAQ: VMAR) has long demonstrated its leadership in marine electrification, with its E-Motion(TM) 180E-powered vessel holding the world record for the fastest electric boat. Set at the annual Lake of the Ozarks Shootout in Missouri, the record shows that VMAR’s craft reached an astonishing speed of 116 mph, surpassing its own previous record of 109 mph, set in 2022 (https://ibn.fm/LKHj1). This enduring achievement continues to underscore Vision Marine’s commitment to innovation and excellence in the electric marine industry.

“We’re in a bold new development and training phase, and Vision Marine is becoming the reference in America for electric boating,” said Vision Marine Technologies CEO and cofounder Alexandre Mongeon. “When we broke the record, we proved that electric boating can compete at the highest levels of performance. Today, that same technology is validated and available to customers through Florida’s strongest dealer platform. We remain faster than 80% of ICE boats at the Ozarks, underscoring our enduring performance edge, while building a sustainable foundation that creates lasting value for investors. Once the record is challenged, we will return with determination to push the boundaries even further.”

Founded in 2018, Vision Marine Technologies is a Canadian company specializing in the development and manufacturing of electric propulsion systems for the marine industry. Vision Marine’s mission is to revolutionize the boating experience by providing sustainable, high-performance electric solutions that cater to a growing demand for ecofriendly recreational watercraft.

The company’s flagship product, the E-Motion 180E, is a high-performance, 180-horsepower electric outboard motor designed to deliver exceptional speed and efficiency. So far, the E-Motion 180E has been successfully integrated into 25 different boat platforms, including pontoons, bowriders, dual consoles, center consoles and catamarans. This versatility demonstrates the adaptability of Vision Marine’s technology across various vessel types, making electric propulsion accessible to a broader range of boating enthusiasts.

In addition to its technological advancements, Vision Marine has established a robust distribution network through its Nautical Ventures division, which operates nine retail locations across Florida. With annual boat sales exceeding $100 million and a customer database of more than 50,000 boaters, Nautical Ventures provides a strong foundation for the widespread adoption of Vision Marine’s electric propulsion systems.

The company’s commitment to sustainability is further exemplified through its partnership with Octillion Power Systems, which supplies the high-performance battery packs for the E-Motion 180E (https://ibn.fm/XaGk6). These advanced battery systems ensure optimal performance and longevity, contributing to the overall efficiency and reliability of Vision Marine’s electric vessels.

Vision Marine Technologies’ dedication to innovation and sustainability has positioned it as a leader in the electric marine industry. With its world record–setting achievements, versatile propulsion systems and strong distribution network, the company is well equipped to meet the growing demand for eco friendly recreational boating solutions. As the marine industry continues to evolve, Vision Marine remains at the forefront, driving the transition toward a more sustainable and electrified future.

For more information, visit www.VisionMarineTechnologies.com.

NOTE TO INVESTORS: The latest news and updates relating to VMAR are available in the company’s newsroom at https://ibn.fm/VMAR

• Strawberry Fields REIT generated $18.9 million in AFFO and $8.7 million in net income for the second quarter of 2025.
• Rental income rose 29% year-over-year, reflecting growth from acquisitions and lease renewals.
• The company owns and leases 142 healthcare facilities with over 15,500 licensed beds across 10 states.
• Long-term triple-net leases with built-in escalators support predictable, recurring revenue.
• Recent acquisitions in Missouri and Oklahoma added $7.1 million in new annual base rent.

Strawberry Fields REIT (NYSE American: STRW) is a self-administered real estate investment trust engaged in the ownership, acquisition, development, and leasing of skilled nursing and other healthcare-related properties. Initially spun out in 2015 with a 33-property portfolio in Indiana and Illinois, the company has steadily expanded its footprint and now owns and leases across 10 states. Its facilities are leased to experienced third-party operators, primarily under long-term triple-net agreements.

The company’s disciplined strategy emphasizes working with regional operators and experienced consultants, focusing on markets where demographic tailwinds and regulatory barriers support long-term demand. From 2020 through projected 2025, the company achieved compound annual growth rates of 13.6% in Adjusted Funds From Operations (“AFFO”) and 13.5% in Adjusted EBITDA (“AEBITDA”).

In August 2025, the board of directors approved a 14.3% increase in the company’s quarterly dividend to $0.16 per share. Chairman and CEO Moishe Gubin stated that the dividend increase reflects the company’s strong performance and sustainable outlook, while still keeping the payout ratio below 50%.

Strawberry Fields REIT is headquartered in South Bend, Indiana.

Portfolio

As of September 2025, Strawberry Fields REIT owns and holds long-term leasehold interests in 142 healthcare facilities totaling more than 15,500 licensed beds. The portfolio includes 130 skilled nursing facilities (“SNFs”), 10 assisted living facilities (“ALFs”), and two long-term acute care hospitals (“LTACHs”), with properties located in Arkansas, Illinois, Indiana, Kansas, Kentucky, Missouri, Ohio, Oklahoma, Tennessee, and Texas.

In recent months, Strawberry Fields REIT has expanded its portfolio through the following acquisitions:

• Nine skilled nursing facilities in Missouri totaling 686 beds for $59 million. Eight of the facilities were added to an existing master lease with the Tide Group, increasing annual base rent by $5.5 million, while the ninth facility was added to Reliant Care Group’s lease, raising rent by an additional $0.6 million.
• An 80-bed skilled nursing facility near Oklahoma City, Oklahoma, for $4.25 million, which was leased to a current operator under a master lease with $425,000 of initial rents and 3% annual escalations.
• A 124-bed facility comprised of 108 skilled nursing beds and 16 assisted living beds near Poplar Bluff, Missouri, for $5.3 million, which was leased to a current operator under a master lease with $530,000of initial rents and 3% annual escalations.

Market Opportunity

Strawberry Fields REIT operates in the skilled nursing and post-acute healthcare real estate sector, which is supported by favorable demographic and regulatory trends. The U.S. population aged 65 and older is expected to exceed 72 million by 2030 and reach 88.5 million by 2050. According to the CDC, 83.5% of skilled nursing facility residents are 65 or older.

The sector benefits from high barriers to entry, including regulatory constraints, capital requirements, and operational complexity. At the same time, government programs such as Medicare and Medicaid provide a stable reimbursement base. The company noted that despite challenges, its operators have demonstrated consistent profitability in states that are traditionally considered difficult for SNF operators.

Spending on SNF care for the aging population is projected to grow from $181.6 billion in 2021 to $273 billion in 2030, reflecting a compound annual growth rate of 4.63%. Strawberry Fields REIT’s geographic clustering strategy and long-term lease structure position it to benefit from this increasing demand and constrained supply.

Leadership Team

Moishe Gubin, Chairman, CEO, and Founder, has served as CEO since the company’s inception and was involved in every acquisition. He previously served as CFO and manager of Infinity Healthcare Management and is a licensed CPA in New York.

Jeffrey Bajtner, Chief Investment Officer and Chief Operating Officer, joined the company in 2021. He oversees acquisitions, dispositions, and investor relations. Previously, he held leadership roles at BlitzLake Partners and NorthStar Realty Finance. He is a licensed CPA in Illinois.

Greg Flamion, Chief Financial Officer, joined in January 2024. He was formerly CFO at Zimmerman Advertising and has held senior finance roles at Diageo and Bristol Myers Squibb. He holds an MBA from the University of Florida and is a CPA licensed in Indiana.

Steven Greenfield, General Counsel, joined in April 2025. He previously served as Managing Attorney at HammondLaw and held executive and legal positions at Weil, Gotshal & Manges LLP and Mayer Brown LLP, focusing on tax and securities law.

For more information, visit the company’s website at www.StrawberryFieldsREIT.com.

NOTE TO INVESTORS: The latest news and updates relating to STRW are available in the company’s newsroom at https://ibn.fm/STRW

• Public sports stocks have surged in recent years, drawing more institutional and retail investor interest.
• Brera Holdings operates a multi-club ownership strategy spanning Europe, Africa, and Asia.
• The company completed its majority acquisition of SS Juve Stabia, now competing in Italy’s Serie B.
• Juve Stabia’s squad value rose 245% to $32 million during the 2024–25 season.
• Brera is one of only two MCOs active in Italy’s Serie B, alongside City Football Group.
• The firm’s strategy emphasizes portfolio growth, bottom-up value creation, and fan-to-investor pathways.

Public markets have started to embrace sports franchises and related companies in a way rarely seen before. While historically only a handful of clubs and sports organizations went public, the trend has gained momentum, with sports-related stocks across multiple categories delivering strong gains in recent years, according to a Profluence analysis (https://ibn.fm/5IU6R).

Brera Holdings (NASDAQ: BREA), an Ireland-based international holding company, has built its strategy around multi-club ownership (“MCO”), a model that is increasingly attracting capital. The company is expanding its global portfolio of men’s and women’s football clubs, offering investors a direct way to participate in the growth of the sports sector.

Brera’s latest expansion came with its completed acquisition of SS Juve Stabia on June 20, 2025. The Serie B club, often referred to as “The Other Team of Naples,” enjoyed a successful 2024–25 season. After securing promotion from Serie C, the team advanced to the semifinals of the Serie A promotion playoffs. Its player roster and squad valuation grew significantly, with Transfermarkt and Social Media Soccer data estimating a 245% increase to $32 million.

This performance underscored the financial upside potential in Brera’s approach. By targeting emerging clubs and driving value through performance, sponsorships, and fan engagement, Brera demonstrates how sports investments can generate measurable returns beyond traditional broadcasting or ticket revenues.

With the Juve Stabia acquisition, Brera became the second MCO operator in Italy’s Serie B. The only other multi-club entity in the league is City Football Group, the Abu Dhabi-backed owner of Manchester City and Palermo FC. This positioning places Brera among a small group of firms leveraging the MCO model at scale in European football.

The company’s portfolio now stretches across multiple geographies. Following the acquisition of Brera FC in Milan in 2022, it has expanded into Africa with Brera Tchumene FC in Mozambique, into Eastern Europe with Brera Strumica FC in North Macedonia, into Asia with Brera Ilch FC in Mongolia, and into women’s football with Brera Tiverija FC. Each move has aligned with its strategy of acquiring undervalued clubs with potential for rapid development.

The broader sports investing market has become increasingly diverse. Publicly traded entities now range from traditional franchises like Madison Square Garden Sports and Liberty Media’s Formula 1 to hybrid assets such as TKO Group, the parent of UFC and WWE. Investor appetite is driven not just by team performance but by the ancillary revenue streams tied to media, real estate, and sponsorship.

Brera’s focus on emerging clubs offers a different angle. Rather than competing for marquee assets, it applies a bottom-up approach, seeking to unlock value where mainstream capital is not yet concentrated. This resembles how private equity has entered the sports space, deploying capital into teams and leagues that were previously off-limits.

A notable aspect of sports investing is the overlap between fan engagement and shareholder interest. Supporters of clubs have shown increasing willingness to invest in teams, whether through formal share offerings or indirect investments. Brera’s strategy aligns with this dynamic, as its growth across markets builds new communities of fans who may eventually also become investors.

This blending of emotional and financial equity is one of the reasons analysts expect more sports assets to test public markets in the future. The Brera model, with its diversified footprint and accessible entry point for investors, reflects this evolution.

While the number of publicly traded sports franchises remains small compared with the size of the industry, the pipeline is expected to expand. For investors, companies like Brera Holdings provide a rare listed option to gain exposure to the growth of professional football clubs and the wider sports ecosystem.

By combining geographic expansion, value-driven acquisitions, and socially impactful initiatives such as the UEFA-recognized FENIX Trophy, Brera is carving out a place in a market where both capital and fan interest are on the rise.

For more information, visit the company’s website at www.BreraHoldings.com.

NOTE TO INVESTORS: The latest news and updates relating to BREA are available in the company’s newsroom at https://ibn.fm/BREA

• GlobalTech’s mission is centered on creating exponential value for its portfolio companies while delivering measurable results for shareholders
• A key component of the company’s strategy is the establishment of AI and Big Data Center of Excellence (“CoE”), that focus on advanced technology development
• While the company’s broader mission drives its long-term vision, GlobalTech recently reported financial results for Q2 2025

GlobalTech (OTC: GLTK) is a U.S.-based technology holding company at the forefront of innovation, specializing in artificial intelligence (“AI”), big data and digital infrastructure. With a mission to empower visionary companies and innovation-led enterprises, GlobalTech focuses on enabling growth through strategic partnerships and technology integration.

Founded to leverage the opportunities of the fourth industrial revolution, GlobalTech has established itself as a leader in acquiring and accelerating technology-centric assets with strong growth potential (ibn.fm/RWUSQ). The company focuses on businesses and products in AI, big data and other frontier technologies, enabling portfolio companies to scale efficiently, enhance service offerings and expand into new markets. This strategic approach not only maximizes the value of key acquisitions but also fosters long-term innovation and competitive advantage.

GlobalTech’s mission is centered on creating exponential value for its portfolio companies while delivering measurable results for shareholders. The company focuses on enterprises that demonstrate high growth potential, innovative solutions and market relevance, supporting them with the necessary resources to thrive. By integrating cutting-edge technology solutions with capital access and operational expertise, GlobalTech positions its subsidiaries to compete on a global scale, accelerating adoption of transformative technologies across diverse industries.

A key component of GlobalTech’s strategy is the establishment of AI and Big Data Center of Excellence (“CoE”), that focus on advanced technology development. One notable example is its CoE for big data and AI in Pakistan, located within the premises of WorldCall Telecom Limited, a GlobalTech subsidiary (ibn.fm/07R2w). This facility serves as a hub for product development, research and talent cultivation, supporting AI-driven services for corporate, governmental and international clients. With more than 200 workstations and multiple allied offices, the CoE exemplifies the company’s commitment to integrating innovation, operational scalability and human capital development in emerging markets.

Strategic partnerships also form a critical pillar of GlobalTech’s growth model. Collaborations with companies such as Talina AI enable GlobalTech to create AI-driven solutions for global talent acquisition, automating recruitment processes while reducing biases and inefficiencies (ibn.fm/HtDo3). These alliances reflect the company’s broader vision of applying AI and frontier technologies not only to product development but also to operational excellence, transforming how businesses interact with their employees, clients and global partners. By scaling innovative platforms in conjunction with strategic partners, GlobalTech strengthens its market position and expands its ecosystem of technological solutions.

GlobalTech leverages its telecommunications and broadband footprint through WorldCall Telecom Limited’s wireless, long-distance, and international connectivity services, as a strategic enabler that enhances the company’s broader leadership in AI and Big Data. This operational presence enhances GlobalTech’s capacity to integrate digital technologies into telecommunications infrastructure, creating synergies across portfolio companies and providing a robust platform for innovation. The telecom business complements the company’s AI and big data initiatives, supporting applications ranging from smart analytics to digital service optimization.

While the company’s broader mission drives its long-term vision, GlobalTech recently reported financial results for Q2 2025 (ibn.fm/oghCX). The company posted a 23.3% increase in net revenue to $5.63 million, driven largely by a 39% rise in international telecom termination minutes. Operational efficiencies contributed to a narrower adjusted EBITDA loss of $(1.84) million compared to $(2.45) million in Q2 2024. CEO Dan Green highlighted that these results validate the company’s strategic focus on operational optimization and the growing demand for its technology-driven solutions.

“GlobalTech delivered solid revenue growth in Q2 2025, reflecting the strength of our long distance and international (“LDI”), broadband and technology services segments,” said GlobalTech CEO Dan Green. “Our strategic shift toward a service-centric model is yielding positive results, with improved Adjusted EBITDA and reduced net loss. We remain focused on optimizing operations, expanding our FTTH network, and advancing our AI and big data product portfolio to drive long-term value for our shareholders.”

GlobalTech’s long-term vision is to continue leveraging its expertise, capital and technological platforms to create lasting value for its stakeholders. The company’s commitment to building scalable solutions, fostering innovation and delivering results positions GlobalTech as a dynamic force, poised to shape the future of digital enterprise on a global scale. 

For more information, visit www.GlobalTechCorporation.com.

NOTE TO INVESTORS: The latest news and updates relating to GLTK are available in the company’s newsroom at ibn.fm/GLTK

• The company’s lead candidate, OT-101, is currently in a Phase 3 trial for pancreatic cancer and is advancing toward combination studies with checkpoint inhibitors.
• A joint venture with GMP Biotechnology enables Oncotelic to conduct low-cost research and development, operate in-house GMP manufacturing, and support a rapidly expanding nanoparticle pipeline trademarked Deciparticle(TM).
• A strategic partnership with Shanghai Medicilon supports rapid IND filings for up to 20 drug candidates, significantly accelerating development timelines.
• Oncotelic’s proprietary AI platform, PDAOAI, enhances regulatory and research workflows while offering public engagement tools for added transparency.
• The company maintains a multi-indication pipeline spanning oncology, Parkinson’s disease, erectile dysfunction and female sexual Dysfunction, providing broad commercialization potentials.
• Recent peer-reviewed publications support OT-101’s mechanism of action and spotlight TGF-β2 as a survival-linked biomarker in younger PDAC patients.

Oncotelic Therapeutics (OTCQB: OTLC) is a clinical-stage biopharmaceutical company developing RNA-based, immunotherapy, and targeted therapeutics for cancer and other underserved diseases. The company is focused on transforming outcomes for patients with difficult-to-treat and rare conditions, particularly pediatric cancers and aggressive solid tumors. Its development strategy centers on novel compound design, nanoparticle drug delivery, and the integration of artificial intelligence to accelerate discovery and regulatory workflows.

At the center of this foundation is Chairman and CEO Dr. Vuong Trieu, a prolific industry pioneer who has filed more than 500 patents with 75 issued patents across biologics, small molecules, nanoparticles, and diagnostics. Dr. Trieu co-invented Abraxane® (sold to Celgene for $2.9 billion), underscoring his track record of creating high-value therapies. Through collaborations with industry leaders and its stake in specialized joint ventures, Oncotelic is positioned to advance a diverse portfolio of oncology assets with greater speed and cost efficiency. The company also operates a proprietary AI platform, PDAOAI, which streamlines scientific writing, regulatory documentation, and data interpretation. This system is accessible to the public through a dedicated Discord server, offering real-time engagement with Oncotelic’s research ecosystem.

With expanded clinical activity and a next-generation development model, Oncotelic continues to evolve as a multi-asset innovator in precision oncology.

The company is headquartered in Agoura Hills, California.

Pipeline and Partnerships

Oncotelic’s lead candidate is OT-101, currently in a Phase 3 trial for pancreatic ductal adenocarcinoma (STOP-PC study) and evaluated in gliomas and metastatic solid tumors in combination with IL-2 and checkpoint inhibitors. The antisense molecule targets TGF-β2, a cytokine known to suppress immune responses and promote tumor growth. A Phase 1 trial combining OT-101 with IL-2 was recently completed, demonstrating safety and paving the way for combination therapies with PD-1 blockers and other immunotherapies.

Recent data have further strengthened the rationale for OT-101 in pancreatic ductal adenocarcinoma (“PDAC”). In June and July 2025, two peer-reviewed studies published in the International Journal of Molecular Sciences identified TGF-β2 gene expression and methylation status as significant prognostic markers in PDAC, particularly among younger patients and those with low CD8+ T-cell infiltration. High TGF-β2 expression correlated with reduced overall survival, while elevated TGF-β2 methylation was associated with improved outcomes. These findings validate TGF-β2 as a high-priority target and support the continued development of OT-101 as a precision therapy. Both studies leveraged Oncotelic’s proprietary AI-driven platform, PDAOAI, to mine and assemble multi-omic datasets, showcasing the system’s role in accelerating insight generation.

The company holds a 45% ownership stake in GMP Biotechnology Limited, a joint venture with Dragon Capital Overseas Limited. GMP Bio owns SAPU Bioscience, which is executing several pipeline programs. SAPU and Oncotelic are jointly utilizing a rapid IND platform through their partnership with Shanghai Medicilon to support regulatory filings for up to 20 drug candidates, with five INDs already underway. This collaboration is central to accelerating development of next-generation anticancer agents.

After the joint venture, Dr. Trieu, with his team, built out a state of the art and GMP-certified R&D facility in San Diego, which operates under SAPU, that manufactures clinical trial materials and supports a proprietary nanoparticle platform trademarked Deciparticle(TM). This platform includes four therapeutic candidates—two of which are in late-stage manufacturing and expected to enter IND filing before the end of 2025.

Additionally, Oncotelic owns AL-101, an intranasal administered apomorphine product intended for the treatment of Parkinson’s disease, Erectile Dysfunction, and Female Sexual Disorders.

Market Opportunity

Oncotelic is targeting large and underserved therapeutic markets with significant commercial potentials. The global pancreatic cancer treatment market alone is projected to grow at a 12.3% CAGR, reaching $5.84 billion by 2030, up from $2.92 billion in 2024, according to Research and Markets. This growth is driven by increased disease prevalence, aging populations, and demand for more effective treatment options. Notably, the incidence of early-onset PDAC is rising at an estimated rate of 4% per year in the 15–34 age group, highlighting an emerging unmet need for targeted therapies among younger patients.

Beyond oncology, Oncotelic intends to develop AL-101 for Parkinson’s disease, which affects over 1 million patients in the U.S. alone and is expected to impact 1.2 million by 2030. Erectile Dysfunction and Female Sexual Dysfunction are also major global health issues, with Erectile Dysfunction affecting up to 70% of men over 60 and Female Sexual Dysfunction impacting approximately 40% of women—both with limited treatment options, particularly for patients who fail to respond to existing medications. These underserved populations offer fertile ground for innovative new therapies.

Leadership Team

Dr. Vuong Trieu is the Chairman and CEO of Oncotelic Inc. An accomplished innovator in pharmaceutical development, Dr. Trieu previously served as President and CEO of Igdrasol, where he pioneered the approval path for paclitaxel nanomedicine via a single bioequivalence trial. After Igdrasol merged with Sorrento Therapeutics, he became Chief Scientific Officer and a Board Director. He also held leadership roles at Cenomed, Abraxis, Applied Molecular Evolution, and Parker Hughes Institute. Dr. Trieu holds a Ph.D. in Molecular Microbiology, a B.S. in Botany, has published widely, and filed over 500 patent applications with 75 issued U.S. patents.

Amit Shah is the Chief Financial Officer of Oncotelic Inc. He has over 20 years of financial leadership in life sciences, including CFO roles at Marina Biotech and Igdrasol, and senior positions at ISTA Pharmaceuticals, Spectrum Pharmaceuticals, and Caraco. He also worked in consulting and ERP implementation. Mr. Shah holds a Bachelor of Commerce from the University of Mumbai, is an Associate Chartered Accountant in India, and is an inactive CPA in Colorado.

Dr. Anthony E. Maida III is the Chief Clinical Officer – Translational Medicine at Oncotelic Inc. He has over 25 years of experience advancing cancer immunotherapies and held senior roles at Northwest Biotherapeutics, PharmaNet, and Jenner Biotherapies. He has raised over $200 million for biotech firms and negotiated licensing deals with institutions such as Pfizer, Eli Lilly, and Yale. Dr. Maida holds dual B.A. degrees in Biology and History, an MBA, an M.A. in Toxicology, and a Ph.D. in Immunology, and is active in ASCO, AACR, and other scientific societies.

For more information, visit the company’s website at www.Oncotelic.com.

NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://ibn.fm/OTLC

Global demand for energy is picking up, in part due to rising power demand fueled by new technologies like AI and EVs. Now, investors can learn new ways to profit at the MoneyShow Virtual Expo, scheduled for Sept. 9-10, 2025. Attendees at the online event will get tips and recommendations across the natural gas, crude oil, and alternative energy sectors.

Participants can also engage with eminent industry veterans to learn novel ways and tools to protect and grow their wealth. MoneyShow Virtual Expos are designed to provide investors and traders with powerful market opportunities and resources to maximize returns. The company has been planning and hosting live and online events for 44 years, providing businesses, exhibitors, and investors with expert advice, resources, and marketing and networking opportunities.

At this MoneyShow bootcamp, experts will share insights and details on both public and private energy sector profit and income opportunities. Dozens of real-time LIVE presentations will also offer current market analysis and actionable takeaways.

The MoneyShow Virtual Expo will also feature virtual booths with message boards, research, videos on investments and trading, and prizes. New and seasoned players can pitch their products and services to gain visibility among traders, investors, and industry experts, while attendees can ask questions of the experts in a highly interactive event format.

Plus, exhibitors can connect with investors in one-on-one Zoom meetings to present their business ideas and plans. Attendees will also have access to a collection of downloadable educational content that they can store in a digital briefcase.

Registrations are open. To know more, please visit https://ibn.fm/qKNBN.

• BreastCT.com launches as a comprehensive educational resource focused on dedicated breast CT technology and IzoView’s clinical advantages for dense breast tissue imaging
• Platform designed to evolve alongside company progression through clinical studies, regulatory phases, and commercial launch milestones
• Strategic positioning within successful imaging category creation context provides clear market reference framework for IzoView’s commercial potential

The Pre-Commercial Challenge: Educating Markets on Breakthrough Technology

Medical device companies developing breakthrough technologies face a fundamental commercialization challenge beyond regulatory approval: market education. When innovations represent genuine advances over existing standards of care, successful adoption requires comprehensive stakeholder education across patients, clinicians, and healthcare administrators.

Izotropic (CSE: IZO) (OTCQB: IZOZF) launched BreastCT.com as a strategic response to this market education requirement, creating a dedicated platform to support awareness initiatives for breast CT technology and the company’s IzoView Breast CT Imaging System.

BreastCT.com focuses specifically on dedicated breast CT technology’s potential to address persistent challenges in detecting breast cancer with dense breast tissue, representing approximately 50% of screening populations. Dense breast tissue creates fundamental imaging challenges for conventional mammography, where overlapping structures can mask cancer and reduce diagnostic confidence.

This limitation affects screening effectiveness for millions of women while creating downstream costs through additional imaging, callbacks, and unnecessary interventions driven by inconclusive results. The educational platform positions IzoView’s capabilities within this clinical context, explaining how dedicated breast CT technology can provide enhanced visualization without compression-related limitations that constrain conventional imaging approaches.

With IzoView’s engineering phase complete, the website serves as a central resource for information about the technology’s clinical advantages and potential applications.

Dynamic Content Strategy Aligns with Development Milestones

Rather than static information delivery, BreastCT.com is designed to evolve alongside Izotropic’s progression through clinical study preparation, regulatory phases, and commercialization activities. This dynamic approach ensures content remains relevant and timely as the company advances through different development stages.

The platform will integrate updates on clinical study design, regulatory milestones, and commercialization planning while maintaining focus on educating audiences about breast CT technology’s clinical advantages. At strategic intervals, Izotropic plans to integrate native advertising campaigns within BreastCT.com to amplify awareness initiatives in alignment with corporate objectives.

Market Context Provides Commercial Framework

BreastCT.com positions Izotropic within broader industry context by highlighting public companies that successfully created and led new imaging categories. This comparative framework gives audiences clear reference points for understanding where breast CT technology could fit within evolving medical imaging markets.

This positioning strategy addresses a common challenge for breakthrough medical technologies: helping stakeholders understand market potential by referencing successful precedents in adjacent categories. The market context demonstrates Izotropic’s sophisticated understanding of commercialization requirements beyond technical development.

Building Recognition Ahead of Clinical Milestones

The BreastCT.com launch occurs as Izotropic prepares for clinical study initiation and regulatory submission activities. This timing enables the company to build stakeholder awareness and market understanding before pivotal clinical data becomes available, creating educated audiences prepared to evaluate study results within appropriate clinical contexts.

Market education platforms prove particularly valuable for companies developing first-in-category technologies, where stakeholders need foundational understanding of new approaches before evaluating specific clinical evidence. The platform supports Izotropic’s broader awareness initiatives, including podcast series and investor outreach activities derived from the company’s comprehensive strategic business plan.

Strategic Foundation for Commercial Success

BreastCT.com represents more than marketing infrastructure; it demonstrates Izotropic’s comprehensive approach to commercialization planning that integrates market education with clinical development and regulatory strategy. Companies that successfully commercialize breakthrough medical technologies typically begin market preparation years before regulatory approval, creating stakeholder awareness that accelerates post-approval adoption.

The educational platform positions Izotropic to capitalize on growing recognition of dense breast imaging challenges while building understanding of how dedicated CT technology can address current screening limitations. The strategic timing of the platform launch, coordinated with IzoView’s engineering completion and clinical study preparation, demonstrates sophisticated commercialization planning.

For more information, visit the company’s website at www.IzoCorp.com

NOTE TO INVESTORS: The latest news and updates relating to IZOZF are available in the company’s newsroom at ibn.fm/IZOZF

• WLDS’s newly granted U.S. patent protects groundbreaking neural interface technology that measures weight, torque, and force directly from wrist-based sensors with applications spanning XR, industrial automation, and assistive technology
• The patent encompasses voice-controlled interfaces and innovations in brain-computer interfaces, strengthening the company’s intellectual property position in the rapidly expanding $260 billion AI wearables market
• Patent protection covers real-world physical measurement capabilities that differentiate WLDS from gesture-only competitors, opening industrial and manufacturing applications beyond consumer electronics

The neural interface revolution is unfolding differently than most technological observers anticipated. While industry attention focused on brain-computer interfaces requiring surgical implants or complex headsets, the real breakthrough is happening at the wrist. Companies are discovering that sophisticated neural signal processing can decode human intent through subtle muscle movements and bioelectric patterns, creating seamless control interfaces that require no learning curve or behavioral adaptation.

This shift represents more than incremental improvement in wearable technology. Traditional gesture control systems rely on visible movements detected by cameras or accelerometers, limiting their utility in professional environments where discrete, precise control is essential. Neural interface technology transcends these limitations by reading EMG signals directly from the wrist, enabling control through imperceptible finger movements and thought-initiated muscle activations.

The commercial implications extend far beyond consumer electronics into industrial automation, medical devices, and assistive technology markets where hands-free operation isn’t convenience, it’s necessity. What distinguishes the current technology wave is the convergence of miniaturized sensors, advanced signal processing algorithms, and artificial intelligence capabilities that enable real-time interpretation of complex neural patterns. Companies that secure intellectual property protection for core neural interface technologies are positioning themselves to capture value across multiple high-growth sectors as these applications scale.

That strategic positioning defines Wearable Devices (NASDAQ: WLDS), a neural interface pioneer that recently secured critical U.S. patent protection for technologies that could redefine human-machine interaction across industries.

Patent Protection Validates Core Technology

WLDS’s newly granted patent titled “Gesture and Voice-Controlled Interface Device” represents significant advancement in neural interface intellectual property. Unlike typical gesture patents focused on movement recognition, this protection covers neural measurement of physical forces: weight estimation, torque measurement for rotating objects, and applied force quantification for precise assembly tasks.

These capabilities transform neural interfaces from entertainment accessories into industrial tools. The patent protects technology that can measure torque when fastening screws, estimate object weight during lifting operations, and quantify connector seating force in cable harness assembly. Such applications address real operational challenges in manufacturing, logistics, and maintenance environments where precise force feedback improves quality and safety.

This measurement precision stems from WLDS’s proprietary approach to neural signal interpretation. Expanding beyond detecting gesture intentions, the technology analyzes muscle activation patterns that correspond to specific physical forces. This enables quantitative feedback that traditional gesture systems cannot provide, creating applications in sectors demanding measurable performance criteria.

Guy Wagner, co-founder and Chief Scientific Officer, emphasized the patent’s strategic importance: “We’re excited to integrate these advanced neural capabilities into our product lines and demonstrate their transformative potential in real-world environments.” This statement signals WLDS’s intention to commercialize beyond consumer applications into industrial markets where neural interface precision creates measurable operational value.

The patent also encompasses voice command integration and extended reality embodiment, protecting WLDS’s comprehensive approach to multimodal neural interfaces. This prevents competitors from circumventing patent protection through alternative input combinations while positioning WLDS to capture value from diverse application scenarios.

Industrial Applications Drive Market Expansion

WLDS’s patent portfolio addresses three distinct market opportunities that leverage neural interface technology differently. Extended reality applications benefit from immersive interaction capabilities that enhance user embodiment without visible gestures that break presence. Industrial and manufacturing environments gain precision measurement tools that improve quality control and worker safety through real-time force feedback.

Manufacturing applications offer immediate commercial opportunities. Assembly line workers performing repetitive tasks benefit from neural feedback that ensures consistent torque application and connection integrity. Quality control processes gain real-time measurement capabilities that detect assembly errors before they propagate downstream.

These applications distinguish WLDS from competitors focused exclusively on consumer gesture control. While entertainment and lifestyle applications drive initial market adoption, industrial use cases provide sustainable competitive advantages through higher switching costs and deeper integration requirements.

Strategic IP Development Supports Growth

WLDS’s patent strategy reflects sophisticated understanding of neural interface commercialization challenges. Rather than pursuing narrow protection for specific implementations, the company secured broad coverage for fundamental measurement capabilities that enable multiple product configurations and application scenarios.

This approach creates both a defensive patent moat and offensive positioning, while preserving commercial flexibility. As neural interface applications expand across industries, WLDS can adapt its technology platform to serve diverse market requirements without requiring fundamental architectural changes. Patent protection ensures competitors cannot replicate core measurement capabilities that differentiate WLDS solutions.

The company’s emphasis on building “a broad and adaptable global patent portfolio covering future applications of wearable bio-potential sensors” indicates systematic IP development aligned with long-term market expansion. This strategic framework positions WLDS to capture value from neural interface adoption across consumer, industrial, and medical markets.

Market Positioning and Commercial Potential

The AI wearables market’s projected growth from $21.2 billion in 2022 to $166.5 billion by 2030 creates substantial opportunities for companies with differentiated neural interface technologies. Neural inputs are the missing link to make AI assistance truly hands-free across platforms, whether on Android devices, iOS ecosystems, or future wearable operating systems, creating a universal interaction layer that device makers cannot ignore.  WLDS’s patent-protected measurement capabilities position the company to serve industrial and medical markets that demand higher precision and reliability than consumer applications.

Neural interface technology adoption follows predictable patterns: early consumer adoption validates core functionality, industrial applications provide sustainable revenue streams, and medical markets offer the highest value opportunities. WLDS’s comprehensive patent protection enables participation across all three market segments while competitors remain limited to specific application areas. While building its patents portfolio, the company is also adapting knowledge from new advances in neuroscience to meet emerging market needs in interfaces to digital devices, AI, and industrial solutions.

The company’s positioning at the intersection of neural sensing, artificial intelligence, and industrial automation aligns with broader technological convergence trends. As manufacturing systems become increasingly automated and responsive, neural interfaces provide natural human-machine communication channels that complement rather than replace existing control systems.

For more information, visit www.WearableDevices.co.il.

NOTE TO INVESTORS: The latest news and updates relating to WLDS are available in the company’s newsroom at https://ibn.fm/WLDS